Monitoring of blood levels in patients administered CYP3A4 inhibitor during the maintenance phase of venetoclax administration

CONCLUSION: The risk of elevated venetoclax blood levels needs to be considered when initiating CYP3A4 inhibitors and reducing venetoclax dosage on the same day.PMID:37969095 | DOI:10.5414/CP204490

Source: International Journal of Clinical Pharmacology and Therapeutics - November 16, 2023 Category: Drugs & Pharmacology Authors: Toshiki Kubo Shunsuke Matsuo Rintaro Sogawa Takeo Yasu Toshiaki Nagaie Sho Okamoto Shinya Kimura Chisato Shimanoe Source Type: research